EuroBiotech: More Articles of Note


> Genfit offloaded the Chinese rights to NASH prospect elafibranor to Terns Pharmaceuticals for $35 million (€31 million) upfront. The deal is worth up to $193 million more in milestones. Statement 

> Boehringer Ingelheim made a milestone payment to Oxford BioTherapeutics after it advanced an oncology drug candidate. Release 

> Vesalius Biocapital closed its third life sciences fund at €120 million. The VC shop had aimed to raise $150 million and close the fund last year. Statement 

Submissions Open

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

> C4X Discovery teamed up with PhoreMost to access technology to support its Parkinson’s disease drug discovery activities. Release 

> Poxel and Sumitomo Dainippon posted top-line data from a phase 3 trial of imeglimin in Type 2 diabetes. The trial met its primary endpoint. Statement 

> Allergy Therapeutics secured a $7.6 million settlement through litigation against Inflamax Research. The case centered on whether a phase 2 allergy trial was performed properly. Release 

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.